丹红注射液治疗慢性心力衰竭的临床疗效与安全性：一项系统评价方案
Clinical efficacy and safety of Danhong injection for the treatment of chronic heart failure: A protocol for systematic review.
作者信息
Han Lihua, Wang Chuan, Yao Dongfeng, Wang Bin, Zhang Zhen, Liu Jiping
机构信息
Department of Pharmacology, College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang.
Key Laboratory of Pharmacodynamics and Material Basis of Chinese Medicine of Shaanxi Administration of Traditional Chinese Medicine.
出版信息
Medicine (Baltimore). 2020 Apr;99(14):e19526. doi: 10.1097/MD.0000000000019526.
BACKGROUND
Danhong injection (DHI) has been widely in the treatment of chronic heart failure (CHF) in China; however, there is not enough clinical evidence DHI for treating CHF.
METHODS
Two researchers will search literatures of DHI for CHF in databases. Extracted data are analyzed with Review Manager 5.3 software. The selected studies should be conducted quality evaluation, forest plots and funnel plots will be run by RevMan5.3.
RESULTS
This systematic review validates the clinical efficacy and safety of DHI in the treatment of CHF through the analysis of New York Heart Association functional classification, left ventricular ejection fraction, left ventricular end-diastolic dimension, cardiac output, brain natriuretic peptide, adverse events.
CONCLUSIONS
This systematic review will be provided a rational clinical evidence to evaluate the effectiveness and safety of DHI for the treatment of CHF.
REGISTRATION NUMBER
PROSPERO CRD42019144686.
背景
在中国，丹红注射液（DHI）已广泛用于治疗慢性心力衰竭（CHF）；然而，尚无足够的临床证据支持DHI治疗CHF。
方法
两名研究人员将在数据库中检索DHI治疗CHF的文献。提取的数据用Review Manager 5.3软件进行分析。对所选研究进行质量评估，并用RevMan5.3绘制森林图和漏斗图。
结果
本系统评价通过分析纽约心脏病协会功能分级、左心室射血分数、左心室舒张末期内径、心输出量、脑钠肽、不良事件，验证了DHI治疗CHF的临床疗效和安全性。
结论
本系统评价将为评估DHI治疗CHF的有效性和安全性提供合理的临床证据。
注册号
PROSPERO CRD42019144686。
Zotero 插件